Recently Immunovaccine, Inc. announced the launch of its DPX-NEO program to foster and expand its DepoVax-based vaccines for use in immuno-oncology clinical settings.
The program was initiated to develop neoepitopes – molecules that are usually the target of an immune response, but in this case are specifically produced by tumor cells. As a result, they are tumor specific and believed to show great promise in the field of immunotherapy, since scientists can design vaccines specifically targeting these tumor-neoepitopes.
In this Oncology Associates video, learn more about how immunotherapy cancer treatment works and what types of side effects it may cause with oncologist Stephen Lemon MD.
Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?